DEVELOPMENT AND MANUFACTURE OF MICROBIAL-DERIVED BIOPHARMACEUTICALS
Richter-Helm is a leading and steadily growing biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with two cGMP-compliant manufacturing facilities in Germany.
We specialize in products derived from bacteria and yeasts. Over the past 30 years we gained substantial experience in the development and manufacture of different product types that include recombinant proteins and peptides, plasmid DNA, and bacterial vaccines.
We move our clients projects forward: flexible, transparent, fast
Our Microbial Capabilities
Our company in numbers
How Richter-Helm Overcomes the Challenges of the Covid-19 Pandemic
Oslo, Norway, December 19, 2022 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has entered into a strategic manufacturing partnership with Richter-Helm BioLogics GmbH & Co KG to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio.
We at Richter-Helm are extremely proud of being awarded the Recruiting-Excellence-Audit® (RExA) of jobware.de. Our whole recruiting processes were analyzed based on hundreds of factors. User-friendliness of the online application form, the job interviews and the onboarding at Richter-Helm all showed great performance. “Richter-Helm responds quickly and professionally to applicants requests. The subsequent onboarding is also exemplary. 83 percent of the new colleagues rated this as good or very good.” stated Jobware.de.
Richter-Helm’s Managing Director Kai Pohlmeyer, Ph.D., and Director of Business Development Thilo Kamphausen, Ph.D., discuss the company’s upcoming expansion in Bovenau, Germany, how pDNA manufacturing is differentiated from more conventional biomanufacturing, and how to ensure and test for the highest level of quality.
Richter-Helm announced today the start of construction for an expansion project at its cGMP manufacturing facility in Bovenau, Germany. The new multi-product biological manufacturing facility is expected to begin full-scale operations and manufacturing by the end of 2023.